Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 35 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2014', provides an overview of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) Overview 6
Therapeutics Development 7
Pipeline Products for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Overview 7
Pipeline Products for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Comparative Analysis 8
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Therapeutics under Development by Companies 9
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Therapeutics under Investigation by Universities/Institutes 10
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Products under Development by Companies 14
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Products under Investigation by Universities/Institutes 15
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Companies Involved in Therapeutics Development 16
Med Discovery SA 16
Novartis AG 17
SATT Lutech SAS 18
Skinvisible Pharmaceuticals, Inc. 19
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 28
BPR-277 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Drug to Inhibit Serine Proteinase for Netherton Syndrome - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MDPK-67b - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit Kallikrein for Netherton Syndrome - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Synthetic Peptide to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables
Number of Products under Development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), H2 2014 7
Number of Products under Development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Comparative Analysis by Unknown Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by Med Discovery SA, H2 2014 16
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by Novartis AG, H2 2014 17
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by SATT Lutech SAS, H2 2014 18
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline by Skinvisible Pharmaceuticals, Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27